Fiona Godlee, editor of the British Medical Journal, denounced risks of collusion between Roche and Novartis in the article "Avastin versus Lucentis".
Notes on verification
The 2012 BMJ editorial by Fiona Godlee exists and its content matches the claim's characterization. Corroborated by pharma trade press and later validated by Italian antitrust authority's 2014 fine on Roche and Novartis for collusion over Avastin/Lucentis, though a related criminal case was later dismissed. [tier=bronze indep_score=0.525 clusters=5 claim_tier=notable | framework convergence=partial (upstreams: British Medical Journal (BMJ), Autorità Garante della Concorrenza e del Mercato (AGCM)) — publishers independent, evidence may not be | kind=attributed eligibility=high]
Sources
- Procedura di infrazione da parte dell'Autorità Antitrust (seed:health_and_medicine)
- https://www.slideshare.net/slideshow/lucentis-fiona-godlee/12817878 (corroboration)
- https://www.agcm.it/media/comunicati-stampa/2014/3/alias-6801 (corroboration)
- https://pharmafile.com/news/197975/novartis-accused-lucentis-campaign-against-avastin (corroboration)
- https://pharmatimes.com/news/novartis_accused_in_uk_avastin_for_wet_amd_row_971259/ (corroboration)
- http://www.fiercepharma.com/story/bmj-novartis-tried-scupper-trials-protect-lucentis-cheap-avastin/2015-04-02 (corroboration)